Kuzich, J.A., Heynemann, S., Geoghegan, N., Evelyn, C., O’Mahoney, S., Wilson, S., et al. (2021) Alectinib Induces Marked Red Cell Spheroacanthocytosis in a Near-Ubiquitous Fashion and Is Associated with Reduced Eosin-5-Maleimide Binding. Pathology, 53, 608-612.
https://doi.org/10.1016/j.pathol.2020.10.023

has been cited by the following article:

• TITLE: Alectinib-Induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma: Case Report and Literature Review

  AUTHORS: Chai Young Lee, Yon Ju Ryu

  KEYWORDS: Non-Small Cell Lung Cancer, Alectinib, Brigatinib, Hemolytic Anemia, Drug-Induced Hemolytic Anemia

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.13 No.8, August 28, 2024

  ABSTRACT: Alectinib is a selective Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor used as standard therapy for ALK-rearranged lung adenocarcinoma. Hemolytic anemia is considered a rare but significant adverse event of alectinib. Here, we report the case of a 78-year-old female with advanced ALK rearrangement-positive lung adenocarcinoma who developed grade 4 drug-induced hemolytic anemia after receiving alectinib as first-line therapy. We discontinued alectinib treatment and switched to brigatinib. As a result, anemia improved without recurrence of lung adenocarcinoma over one year.